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Abstract
Background: Cervical carcinomas are second most frequent type of women cancer. Success in diagnostics of
this disease is due to the use of Pap-test (cytological smear analysis). However Pap-test gives significant portion
of both false-positive and false-negative conclusions. Amendments of the diagnostic procedure are desirable.
Aetiological role of papillomaviruses in cervical cancer is established while the role of cellular gene alterations in
the course of tumor progression is less clear. Several research groups including us have recently named the
protein p16INK4a as a possible diagnostic marker of cervical cancer. To evaluate whether the specificity of p16INK4a
expression in dysplastic and neoplastic cervical epithelium is sufficient for such application we undertook a
broader immunochistochemical registration of this protein with a highly p16INK4a-specific monoclonal antibody.
Methods: Paraffin-embedded samples of diagnostic biopsies and surgical materials were used. Control group
included vaginal smears of healthy women and biopsy samples from patients with cervical ectopia. We examined
197 samples in total. Monoclonal antibody E6H4 (MTM Laboratories, Germany) was used.
Results: In control samples we did not find any p16INK4a-positive cells. Overexpression of p16INK4a was detected
in samples of cervical dysplasia (CINs) and carcinomas. The portion of p16INK4a-positive samples increased in the
row: CIN I – CIN II – CIN III – invasive carcinoma. For all stages the samples were found to be heterogeneous
with respect to p16INK4a-expression. Every third of CINs III and one invasive squamous cell carcinoma (out of 21
analyzed) were negative.
Conclusions: Overexpression of the protein p16INK4a is typical for dysplastic and neoplastic epithelium of cervix
uteri. However p16INK4a-negative CINs and carcinomas do exist. All stages of CINs and carcinomas analyzed are
heterogeneous with respect to p16INK4a expression. So p16INK4a-negativity is not a sufficient reason to exclude a
patient from the high risk group. As far as normal cervical epithelium is p16INK4a-negative and the ratio p16INK4a-
positive/ p16INK4a-negative samples increases at the advanced stages application of immunohisto-/cytochemical
test for p16INK4a may be regarded as a supplementary test for early diagnostics of cervical cancer.
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Background
Cervical cancer makes up about 10–12% of total women
cancers [1,2] with the level of mortality in Russian popu-
lation 5.0 per 100000 [1]. The tendency is being observed
for the past decades towards reduction of both incidence
and mortality. It is mainly due to the population-wide
screening protocols in developed countries which allow
identifying early asymptomatic forms of cervical carcino-
mas. However some problems remain to be solved con-
cerning early detection of this type of cancer.
The main screening test for cervical cancer is the cytologi-
cal smear staining technique developed by G. Papanico-
laou [3] and known as Pap test. Despite evident success
this test gives a substantial rate of both false-positive and
false-negative results.
Histological analysis of a biopsy sample, more laborious
in preparation and study as compared with that of a cyto-
logical smear, is also not absolutely efficient owing to a
substantial rate of interobserver discrepancies among
expert pathologists examining the same material [4].
Infection with human papilloma viruses (HPV) belonging
to so-called high-risk group is the main risk factor of cer-
vical cancer incidence [2]. To detect high risk HPVs in epi-
thelial cells of a patient polymerase chain reaction (PCR)
has been applied during the past two decades [5]. How-
ever this highly sensitive technique cannot resolve the
problem of early cervical carcinoma detection also so far
as many early stage lesions regress and epithelial dysplasia
(i.e. cervical intraepithelial neoplasms, CINs) and carci-
nomas appear only in a minor part of the persons in
whose epithelium (on a smear) high risk HPVs had been
detected [2].
For the recent years several research groups [4,6-16]
including us [11] have dwelt on the protein p16INK4a for a
possible supplementary marker of dysplastic and neoplas-
tic cervical epithelium lesions. This protein belongs to the
group of cyclin-dependent kinase Cdk4/6 inhibitors [17]
and is encoded by tumor suppressor gene INK 4a (syno-
nyms: MTS 1, CDKN2, INK4a/ARF). Gene INK4a plays an
important role in the regulatory pathway Cdk-Rb-E2F.
The product of this gene p16INK4a prevents pRb phospho-
rylation by inactivating Cdk4/6; pRb keeps on binding
E2F transcription factors and as a result cells stay in G1
phase not passing to DNA replication. In various tumor
types INK4a as a bona fide tumor suppressor undergoes
homozygous deletions, is inactivated by point mutations,
LOH or hypermethylation; p16INK4a expression is reduced
or ceases under such conditions or the protein function
may be impaired [18].
Peculiarity of cervical carcinomas is due to the ability of
HPV oncoprotein E7 to interact with pRb and inactivate it
[19]. As a result, the regulatory pathway Cdk-Rb-E2F is
disrupted and the status of gene suppressor INK4a and its
protein becomes of no importance for a cell so far as they
function upstream of the site of breakage. Cells with thus
inactivated pRb pass cell cycle checkpoint G1/S without
any obstacle.
Reciprocallity between status of pRb and that of p16INK4a
commonly found in human permanent cell lines (includ-
ing cervical cell line cultures) [17,20,21] as well as in pri-
mary tumor cells [9,22,23] served for a logical prerequisite
of utilizing p16INK4a protein as a marker of premalignant
and malignant cervical epithelium cells. Functionally
active gene RB was shown to be able to negatively regulate
the expression of INK4a on a transcriptional level, but
details of this negative feed-back loop remain obscure
[24].
To estimate the applicability of p16INK4a as a marker of
dysplastic and neoplastic alterations in cervical epithe-
lium cells we analyzed the expression of this protein uti-
lizing a highly p16INK4a – specific monoclonal antibody.
We examined 197 samples in total. The materials studied
included: 1) samples of normal epithelium of healthy
women (cytological vaginal smears), 2) diagnostic biopsy
samples from patients with cervical ectopia, 3) samples of
CINs of various stages, 4) samples of invasive cervical can-
cer, 5) samples from different normal utery body and cer-
vix tissues from women with gynecological diseases not
associated with dysplastic lesions of epithelium (diagnos-
tic biopsies and surgical materials) and 6) samples of cells
from 3 cervical carcinoma cell lines. We also compare our
data with the results presented by other groups working in
similar directions [4,6-10,12-16].
We demonstrate in the present work that overexpression
of the protein p16INK4a is typical for some samples of dys-
plastic and neoplastic epithelium of cervix uteri. We have
not found at least a single sample overexpressing p16INK4a
among control samples. The portion of p16INK4a-positive
samples increases in the following row: CIN I – CIN II –
CIN III – invasive carcinoma. However p16INK4a-negative
CINs and carcinomas have also been found. All stages of
CINs and carcinomas analyzed turn out to be heterogene-
ous with respect to p16INK4a expression: side by side with
the samples which express p16INK4a in 25% of cells or
more we detect samples which are stained poorly or lack
any staining. So p16INK4a-negativity does not seem to be a
sufficient reason to exclude a patient from the high risk
group when results of Pap-test, HPV detection by PCR or
histological investigation warn about possibility of poor
prognosis. As far as normal cervical epithelium is
p16INK4a-negative and the ratio p16INK4a-positive/BMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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p16INK4a-negative samples increases at the advanced
stages of CINs and carcinomas application of immuno-
histo-/cytochemical test for p16INK4a may be regarded as a
supplementary (optional) test for early diagnostics of cer-
vical cancer.
Methods
Immunohisto-/immunocytochemical study was per-
formed on 197 samples in total. Those included 6 samples
from normal epithelium of healthy women (cytological
vaginal smears taken during regular examination), as well
as the following surgical and diagnostic biopsy materials:
37 samples from patients with cervical ectopia, 113 sam-
ples of CINs of different stages including cancer in situ, 26
samples of invasive cervical cancer (21 squamous cell car-
cinomas and 5 adenocarcinomas), 12 samples of normal
tissues from uterus body (myometrium) and cervix from
patients with different gynecological diseases, 3 cervical
cell line samples taken for positive control (see below).
Apart from 9 smears (which included 6 samples from
healthy women and 3 samples taken from cell cultures
which served as controls) the rest 188 materials were par-
affin-embedded histological blocks. The quality of smears
turned out to be satisfactory for immunochemical analy-
sis (Fig. 1a and 1d).
Neutral formalin-fixed paraffin embedded samples of
biopsies and surgery materials were received from
archives of N.N.Blokhin Cancer Research Center (Mos-
cow), P.A. Gertzen Institute of Oncology (Moscow), Cen-
tral Clinical Hospital (Moscow) and Fourth Clinical
Hospital (Poltava, Ukraine).
For immunohistochemical analysis 4–5 µm serial sections
were transferred on Histobond slides with adhesive layer
(SMT Geraetehandel GmbH, Germany). The first section
was stained with hematoxylin-eosin for traditional mor-
phological analysis and verification of diagnosis by not
less than two independent pathomorphologists.
Presence of high risk HPV in cervical CIN and carcinoma
cells was verified by PCR [25]. Some of the squamous cell
carcinomas were tested by Southern blot hybridization in
addition to PCR. The results of both methods coincided
completely. To detect high-risk HPV in adenocarcinomas
Hybrid Capture 2 test (enabling to detect but not to dis-
cern HPV 16 and HPV 18) was used. The following por-
tions of samples (out of those studied
immunochemically) were analysed for high-risk HPV
genetic material: CINs I – 9/51, CINs II – 9/32, CINs III –
19/24, invasive squamous cell carcinomas – 21/21, aden-
ocarcinomas – 5/5. This study did not cover all CINs
which we studied immunochemically due to the tiny size
of most of those samples.
Vaginal normal epithelium smears obtained during regu-
lar examination from healthy women were transferred on
HistoBond slides. Absence of abnormal cells was con-
firmed in Cytology Department of Cancer Research
Center on a parallel slide. Smears were fixed for 5 min in
10% formaldehyde, washed with flowing water, and proc-
essed for further development as described for deparaffin-
ized histological slices [9]. Cells of cervical cell lines were
cultured under standard conditions in DMEM supple-
mented with 10% of foetal bovine serum. For immunocy-
tochemistry cells were taken during culture receeding,
dropped in a culture medium on a Histobond slide, air-
dried and then processed identically to smears from
healthy women.
Immunohistochemical staining was carried out using
p16INK4a-specific monoclonal antibodies E6H4 (MTM
Laboratories AG, Germany) according to protocol by
Klaes et al [9].
Controls in the course of immunohistochemical studies 
were as follows
Positive controls
1). In the beginning of the study as a whole cells of three
cervical cell lines were stained first. They were SiHa
(HPV16-positive), C33a and HT-3 (both HPV-negative);
all of them had been characterized as expressing the pro-
tein p16INK4a in earlier immunocytochemical studies with
the same antibody [9]. 2). One HT-3 cell slide was stained
in parallels with the first series of biopsy materials. 3).
Every next group of slides intended for staining compul-
sorily included the slide with one of the serial sections of
the CINIII or invasive carcinoma sample which had been
characterized as a p16INK4a-positive one in our previous
studies (on preceeding cuts). The analysis of the given
slide series was carried out only if the positivity of the con-
trol sample was confirmed. Thus neither slide series in the
present study was completely p16INK4a-negative.
Negative controls
1). One more serial cut made from p16INK4a-expressing
material was included into every slide series meant for
staining (as in variant 3 of positive controls, – see above)
which was processed in a usual way but PBS was applied
instead of p16INK4a-specific antibody. The results were
regarded as valid if this slide was negative. 2). As an intrin-
sic negative control served adjacent to CIN or carcinoma
normal tissues including stromal elements. In neither case
did we find any staining in these tissues (fig. 1c).
In addition to four categories of staining defined by Klaes
et al. [9],- poor (less than 1% of stained cells,- figure 1b),
sporadic (1–5% of stained cells, – figure 1b), focal (cell
clusters were stained but not more than 25% of cells were
positive, – figure 2a) and diffuse (more than 25% of cellsBMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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were stained, – figures 1c and 2c,2f,2g,2h), we formed one
more group (negative) of those samples which totally
lacked any stained cells (Figures 1a, 2b,2d and 2e). We
regarded those cells as stained in which p16INK4a was
expressed in nuclei and/or in a cytoplasm.
Results
Various types of p16INK4a-specific staining of cervix uteri
normal, dysplastic and cancer cells are presented in Fig.
1a,1b,1c,1d and Fig. 2a,2b,2c,2d,2e,2f,2g,2h.
We did not register any staining in either of 6 smear sam-
ples taken from healthy women (Fig. 1a). An example of
a very poor cytoplasmic staining in some separate CIN I
cells with a more pronounced (sporadic, both nuclear and
cytoplasmic) staining in the adjacent cancer in situ cells is
shown in Fig. 1b. In one invasive carcinoma we detected
cytoplasmic staining in the predominant majority of can-
cer cells while but sole nuclei turned out to be stained
(Fig. 1c); the boundary between cancer and normal tissues
coincided with the line at which the staining discontin-
ued. As to the cervical cells cultivated in vitro taken for
positive controls, in HT-3 cells the specific staining was
strongly manifested both in nuclei and in a cytoplasm
(Fig. 1d) while in SiHa and C33a cells it was exclusively
cytoplasmic. It is not clear yet why in one and the same
cervical cancer sample the protein p16INK4a  (normally
showing its activity in nuclei) may be detected but in a
cytoplasm in the majority of cells while in a number of
cells both in nuclei and cytoplasm, why in some cervical
cell cultures it is found solely in cytoplasm and in other
cervical cell lines – in nuclei also. We did not find at least
a single sample with an exceptionally nuclear staining;
similar were the results by other investigators [9]. With
keeping in mind that subcellular location of p16INK4a-spe-
cific staining varies to such a degree we scored as positive
every sample in which the staining was expressed either in
a cytoplasm or in both nuclei and cytoplasm.
Different types of cervical cell staining with the p16INK4a-specific antibodies Figure 1
Different types of cervical cell staining with the p16INK4a-specific antibodies. a. Normal epithelium (smear): negative staining. b. 
CIN I (indicated with a dotted arrow) and cancer in situ (solid arrows): a very poor cytoplasmic staining in separate CIN I cells 
and sporadic staining in cancer in situ. c. Invasive squamous cell carcinoma. Diffuse cytoplasmic staining with the sole cell 
expressing p16INK4a in the nucleus (solid arrow). The boundary with adjoining normal tissue is marked with a dotted arrow. d. 
HT3 cells (smear) with both nuclear and cytoplasmic subcellular location of the positive staining.BMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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Cervical tissue samples after immunohistochemical staining with p16INK4a-specific antibodies Figure 2
Cervical tissue samples after immunohistochemical staining with p16INK4a-specific antibodies. a. CIN I. Focal staining. b. CIN II. 
Negative staining. c. Cancer in situ (indicated with an arrow) and CIN III. Diffuse staining. d. CIN III. Negative staining. e. Squa-
mous cell carcinoma. Negative staining. f. Squamous cell carcinoma. Diffuse staining. g. Squamous cell carcinoma embol. Diffuse 
staining. h. Adenocarcinoma. Diffuse staining.BMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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The data of the analysis of the cervical epithelium prepa-
rations stained with monoclonal antibodies E6H4 are
summarized in Table 1.
In all 37 samples from patients with cervical ectopia
p16INK4a-positive cells were observed with low frequen-
cies: 34 samples were negative and 3 ones (8,1%) were
stained poorly.
In the group of CINs I 63% of the samples were p16INK4a-
negative. In 7 samples (about 14%) sporadic or focal (Fig.
2a) type of staining was observed.
Group of CINs II turned out to be highly heterogeneous
in terms of the ratio of p16INK4a-positive cells as well. Most
of these samples (68%, 26 out of 38, Fig. 2b) did not differ
from the samples of normal epithelium, but the rest 12
samples we attributed to poor, sporadic or focal types. In
neither sample of CIN I or CIN II did we observe diffuse
staining for p16INK4a.
Among the samples of CIN III about 54% (13 out of 24)
were attributed to sporadic (Fig 1b), focal or diffuse (Fig.
2c) types. However every third CIN III sample was found
to be p16INK4a-negative (Fig. 2d).
As to invasive cancers, only 1 out of 26 samples (3.8%)
lacked p16INK4a-positive cells (Fig. 2e). One sample
expressed the marker poorly. In 24 cases sporadic, focal or
diffuse staining was observed. Diffuse staining was regis-
tered in about 50% of these samples (Figs. 1c, 2f,2g,2h).
Among 14 samples of invasive carcinomas which had
been stored in paraffin blocks for 7 years 1 (7.1%) turned
out to be p16INK4a-negative, 1 (7.1%) stained poorly, 3
(21.4%) stained sporadically, 4 (28.4%)-focally and 5
(35.8%) expressed diffuse staining.
We have examined several cases with more than one type
of lesion on the same slide. Examples are presented on
Figures 1b and 2c. As a rule in combined cases p16INK4a
expression was more pronounced in cells belonging to a
more advanced lesion (Fig. 1b).
All the HPV-tested samples of CINs and invasive squa-
mous cell carcinomas were high-risk HPV-positive (data
on CINs I and CINs II are shown in the additional file,
results with CINs III and squamous cell carcinomas – in
Table 2). High-risk HPVs were also found in all the sam-
ples of adenocarcinomas.
In reference group composed of samples from normal
uterus body and cervix uteri tissues obtained from
patients with gynecological diseases (stromal and glandu-
lar tissues of the cervix from patients with cervical ectopia
from which squamous cell epithelium had been fully cut
off; myometrium of uterus body from the patient after
surgery for cervical carcinoma) the results of staining with
p16INK4a-specific antibodies were negative in all 12 cases
(Table 3).
Discussion
Immunochemical detection of p16INK4a by monoclonal
antibodies shows that the overwhelming majority of
invasive cervical carcinoma samples differ from normal
cervical epithelium of healthy women. We found no cases
of sporadic, focal or diffuse staining with E6H4 antibodies
among 6 vaginal smears from healthy women as well as
among 37 samples from patients with cervical ectopia
including those in which ectopically localized cervical epi-
Table 1: p16INK4a EXPRESSION IN NORMAL, DYSPLASTIC AND NEOPLASTIC EPITHELIAL CELLS OF CERVIX UTERI
STAINING*
MATERIALS number of samples negative poor sporadic focal diffuse
Normal epithelium (smears) 6 6 (100) - - - -
Cervical ectopia including 37 34 (91,9) 3 (8,1) - - -
C.e. + coilocytosis 10 9 1 - - -
C.e. + condyloma 2 1 1 - - -
Dysplasia:
CINs I 51 32 (62,7) 12 (23,5) 6 (11,8) 1 (2,0) -
CINs II 38 26 (68,4) 7 (18,4) 4 (10,5) 1 (2,7) -
CINs III including cancer in situ 24 8 (33,3) 3 (12,5) 7 (29,2) 2 (8,3) 4 (16,7)
Invasive carcinomas including squamous cell 
carcinomas adenocarcinomas
26 1 (3,8) 1 (3,8) 4 (15,5) 7 (26,9) 13 (50,0)
Squamous cell carcinomas 21 1 (4,8) 1 (4,8) 3 (14,3) 6 (28,5) 10 (47,6)
Adenocarcinomas 5 - - 1 (20,0) 1 (20,0) 3 (60,0)
* percent is given in parenthesisBMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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thelium koilocytes or condyloma had been registered. In
addition, in 11 samples of normal glandular and stromal
cervical tissues and one sample of uterus body normal
myometrium tissue which were obtained from patients
with gynecological disorders p16INK4a was not expressed at
all.
The predominant majority of invasive carcinoma samples
were both high-risk HPV-positive and p16INK4a-express-
ing. However in 2 samples not expressing any p16INK4a or
expressing it poorly high-risk HPV DNA sequences were
detected by both PCR and Southern blot hybridization.
These data are in a good agreement with those by Klaes et
al., who described two samples of p16INK4a-negative but
HPV-positive cervical cancer [9]. Among CIN III samples
which were stained in our experiments poorly or lacked
any staining (table 2, samples 1–6) high risk HPVs were
found in 6 out of 6 tested. As to CIN I and CIN II samples
expressing p16INK4a in less than 1% of cells (1 data, sam-
ples 1–5 and 10–14, respectively), we did not find any
high-risk HPV-negative case in those groups either.
Thus there seem to exist dysplastic and neoplastic lesions
of cervix uteri which do not overexpress the protein
p16INK4a but harbor high-risk HPV DNA.
We confirm the data by Klaes et al. [9] that prolonged (for
7 years in our case) preservation of cervical carcinoma
samples in paraffin blocks does not preclude the material
from diffuse staining.
Monoclonal antibodies E6H4 originally described by
Klaes et al [9] had been tested by those authors among a
number of clones of p16INK4a-specific monoclonal anti-
bodies. The following commercially available clones had
been taken: 1). DCS-50.1/H4-NA29 (Oncogene Research
Products, Cambridge, MA), 2). 375P (Biogenex Laborato-
ries, San Ramon, CA), 3). ZJ11 and JC8 (NeoMarkers,
Freemont, CA), 4) 05–418 (Upstate Biotechnology, Lake
Placid, NY) and 5). J175–405 (PharMingen, San Diego,
CA). The results of the comparative experiments by Klaes
at al [9] had demonstrated that clone E6H4 had turned
out to be the most specific as inferred on the lowest level
of unspecific staining on different tumor cell lines, both
HPV-negative and positive. As in our experiments Klaes et
al. [9] registered mainly cytoplasmic staining both in cells
of permanent cell lines and in preneoplastic and carci-
noma samples; an exclusive nuclear staining was not
detected.
We observed strong p16INK4a-positivity (sporadic or focal
staining) in a comparatively small number of CIN I and
CIN II samples (13–14 %). Among CINs III the portion of
such samples increased up to 54,2%, with diffuse staining
in every sixth case.
The data we have obtained for CINs of all stages rather dif-
fer from the results by Klaes et al. [9]. All of CINs II and
CINs III were stained as diffuse by Klaes et al. [9]. In the
present study the group of CINs as a whole is much more
heterogeneous. The reasons for those discrepancies are
not quite clear yet. The population of Russian and Ukrain-
ian patients whose materials were used in the present
study was extremely heterogeneous with respect to age,
Table 2: Data on high risk HPV genome detection by PCR in CIN 
III and invasive squamous cell carcinoma samples
Sample No Type of immunochemical staining HPV type
CINs III
1 negative 16
2 negative 18
3 negative 16
4p o o r 1 6
5p o o r 1 6
6p o o r 1 6
7s p o r a d i c 1 6
8s p o r a d i c 1 6
9s p o r a d i c 1 6
10 sporadic 16
11 sporadic 16
12 sporadic 16
13 sporadic 16
14 focal 16
15 focal 16
16 diffuse 16
17 diffuse 16
18 diffuse 18
19 diffuse 18
invasive squamous cell carcinomas
20 negative 16*
21 poor 16*
22 sporadic 16*
23 sporadic 16
24 sporadic 16*
25 focal 16*
26 focal 16
27 focal 16
28 focal 18
29 focal 16
30 focal 16
31 diffuse 16
32 diffuse 16
33 diffuse 16
34 diffuse 66
35 diffuse 16
36 diffuse 16
37 diffuse 16
38 diffuse 16
39 diffuse 18
40 diffuse 16 + 18
* confirmed by Southern blottingBMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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nationality, etc. We cannot exclude that the discrepancies
mentioned may be due to these factors as had been dis-
cussed earlier [26].
Nevertheless the coincidence between our results and the
data by Klaes et al [9] concerning the general trend seems
much more important: the increase of p16INK4a expression
in dysplastic and neoplastic cervical epithelium in the
course of progression.
This trend is especially evident in our study when negative
cases only are taken into consideration. All 6 samples were
p16INK4a-negative in control group. Similar was the situa-
tion in the reference group: 12/12 negative. Among CINs
I, CINs III and invasive carcinomas these indices made up
32/51 (63 %), 8/24 (33%) and 1/26 (4 %) respectively.
The data presented herein allow us to conclude that
hyperexpression of p16INK4a when detected immunohisto-
chemically may be regarded as a marker of dysplastic and
neoplastic lesions in cervical epithelium. Positive correla-
tion between p16INK4a  expression and morphological
stage of the disease on the same slide (when combined
cases with both dysplastic and neoplastic lesions were
found) also favors this inference.
In a number of recent communications immunochemical
staining for p16INK4a was suggested to be performed on
cytological smears [9,13-15]. Cytological approach has
some advantages, so far as it enables a patient to avoid sur-
gical intervention. That is why one may expect in the near-
est future immunocytochemical version for detecting
p16INK4a to become rather widely used not only as an
addition to surgery but also for regular examinations in
outpatient clinics. In this connection it seems important
to estimate frequencies of a feasible false-negativity of the
test.
Keeping in mind that dysplastic lesions of all stages fre-
quently regress and do not convert into invasive cervical
carcinomas [2], we summarized the data by different
groups on the frequencies of p16INK4a-negative invasive
carcinoma samples (Table 4). We found that p16INK4a-
negative cervical adenocarcinomas had been detected
Table 3: STAINING OF THE REFERENCE MATERIALS WITH p16INK4a-SPECIFIC MONOCLONAL ANTIBODIES
MATERIALS number of samples negative poor sporadic focal diffuse
Normal tissues, including 12 12 - - - -
Uterus body (myometrium) 1 1 - - - -
Stromal and glandular tissues of cervix 
uteri
11 11 - - - -
Table 4: THE SHARE OF p16INK4a-NEGATIVE SAMPLES AMONG CERVICAL CARCINOMAS (LITERATURE DATA)
Research group (reference) The share (per cent) of p16INK4a-negative samples
among adenocarcinomas:
Lu et al, 1998 (7) 17/40 (42.5%)
Sano et al, 1998 (8) 4/15 (26.7%)
Milde-Langosch et al, 2001(10) 8/58 (13,8%)
Klaes et al, 2001(9) 1/7 (14.3%)
Saqi et al, 2002 (13) 0/2 (0%)
Murphy et al, 2003 (14) 0/2 (0%)
Negri et al, 2003 (15) 0/18 (0%)
Agoff et al, 2003 (16) 2/7 (28.6 %)
Present study 0/5 (0%)
among squamous cell carcinomas:
Wong et al, 1997 (6) 8/79 (10.1%)
Sano et al, 1998 (8) 1/39 (2.8%)
Klaes et al, 2001 (9) 1/53 (1.9%)
Sano et al, 2002 (12) 0/34 (0%)
Klaes et al, 2002 (4) 0/46 (0%)
Saqi et al, 2002 (13) 0/1 (0 %)
Murphy et al, 2003 (14) 0/8 (0%)
Agoff et al, 2003 (16) 4/46 (8.7%)
Present study 1/21 (4.8%)BMC Cancer 2004, 4:58 http://www.biomedcentral.com/1471-2407/4/58
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with frequencies which had varied from 0% up to 42,5%
while p16INK4a-negative squamous cell carcinomas – with
frequencies that had not exceeded 10,1%. Substantial
variability of the data may be due to small numbers of
samples analyzed (in some of the studies), to utilization
of different types of monoclonal antibodies, to different
criteria used by different research groups for the results
interpretation, etc.
It seems important to realize the proper place of immuno-
cyto-/ immunohistochemical analysis of p16INK4a expres-
sion among previously developed tests for early detection
of cervical carcinomas. In this connection the following
points deserve mentioning. A pathologist in the course of
common histological investigation usually registers some
morphologic features such as zones of active mitotic divi-
sions, multipolar mitoses, vicinity of condilomas and
other formations. However when performing an immu-
nocytochemical analysis on a smear a cytologist cannot
bring in a correlation with morphological structure results
of staining with p16INK4a-specific antibodies in separate
cells. According to the results of the present study about
33% of CINs III as well as about 5% of invasive squamous
cell carcinomas of cervix uteri do not differ from normal
cervical epithelium with respect to p16INK4a expression.
Thus immunochemical staining for p16INK4a  (in both
cyto- and histochemical versions) does not seem to be the
approach that can help to fully overcome absolutely all
existing ambiguities of cervical cancer early diagnostics.
As to possible sources of false positivity of immunochem-
ical detection of the protein p16INK4a the study by Agoff et
al [16] deserve mentioning. According to this communi-
cation in 10 out of 10 endometrial biopsy samples studied
endometrial cells were positively stained with the
p16INK4a – specific antibody E6H4. So far as endometrial
cells may occur on vaginal smears the test does not seem
to enable one to fully avoid false positivity.
Conclusions
Overexpression of the protein p16INK4a encoded by tumor
suppressor gene INK4a is a characteristic of displastic and
neoplastic alterations of cervical epithelium. The portion
of p16INK4a-positive samples increases in the following
row: CIN I – CIN II – CIN III – invasive carcinoma. All
stages of CINs and carcinomas analysed are heterogene-
ous with respect to p16INK4a expression: side by side with
the samples which expressed p16INK4a in 25% of cells or
more we detected samples which were stained poorly or
lacked any staining. According to the data we present
herein p16INK4a-negative cervical neoplasms and carcino-
mas do exist. Thus the lack of p16INK4a-positive cells in
samples from different types of cervical lesions should not
be regarded as a sufficient reason for excluding a patient
from the high-risk group. Despite this as far as normal cer-
vical epithelium is p16INK4a-negative and the ratio
p16INK4a-positive/ p16INK4a-negative samples increases at
the advanced stages of CINs and carcinomas application
of immunohisto-/cytochemical test for p16INK4a may be
regarded as an additional (optional) test for early detec-
tion of precancerous lesions in cervical epithelium.
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